A metabolic dependency of EBV can be targeted to hinder B cell transformation
Müller-Durovic B, Jäger J, Engelmann C, Schuhmachers P, Altermatt S, Schlup Y, Duthaler U, Makowiec C, Unterstab G, Roffeis S, Xhafa E, Assmann N, Trulsson F, Steiner R, Edwards-Hicks J, West J, Turner L, Develioglu L, Ivanek R, Azzi T, Dehio P, Berger C, Kuzmin D, Saboz S, Mautner J, Löliger J, Geigges M, Palianina D, Khanna N, Dirnhofer S, Münz C, Bantug G, Hess C, Berger C, Hess C, Koller M, Rossi S, Stampf S, Müller N. A metabolic dependency of EBV can be targeted to hinder B cell transformation. Science 2024, 385: eadk4898. PMID: 38781354, DOI: 10.1126/science.adk4898.Peer-Reviewed Original ResearchConceptsEpstein-Barr virusIndoleamine 2,3-dioxygenase 1B-cell transformationB cellsEBV-driven B-cell transformationIndoleamine 2,3-dioxygenase 1 expressionIndoleamine 2,3-dioxygenase 1 inhibitionInfection of B cellsEBV-infected B cellsEnzyme indoleamine 2,3-dioxygenase 1Epstein-Barr virus protein EBNA2Increased IDO1 activityNicotinamide adenine dinucleotideDevelopment of lymphomaEBV-related diseasesInfected B cellsHumanized miceTransplant patientsImmune dysregulationAdenosine triphosphateMitochondrial complex I activityComplex I activityMetabolic vulnerabilitiesIDO1 activitySerum signature
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply